Prospective, multi-center, single arm, post approval study to be conducted in the United States.
Evaluate the effectiveness of Boston Scientific (BSC)'s LV MSP (Left Ventricular MultiSite Pacing) feature in the Resonate family of CRT-D devices and confirm safety in a post approval study when used in accordance with its approved labeling.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
OTHER
Masking
NONE
Enrollment
586
Left Ventricular MultiSite Pacing
LV MSP Feature Related Complication-Free Rate
Proportion of subjects free from LVMSP feature related complications at 12 months
Time frame: Between 6 month visit and the 12 month visit in non-responders with LV MSP on for any duration.
Proportion of LV MSP Group Subjects With an Improved Clinical Composite Score at 12 Months
Proportion of non-responders with LV MSP enabled at 6 months who were responders at 12 months. Responders were defined as having an Improved Clinical Composite Score at 12 Months.
Time frame: 12 Month Follow Up
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Mobile Infirmary Medical Center
Mobile, Alabama, United States
Phoenix Cardiovascular Group
Phoenix, Arizona, United States
Cardiology Associates of NEA
Jonesboro, Arkansas, United States
Foothill Cardiology Medical Group
Arcadia, California, United States
Chula Vista Cardiac Center
Chula Vista, California, United States
Kaiser Permanente Los Angeles Medical Center
Los Angeles, California, United States
Desert Heart Rhythm Consultants
Palm Springs, California, United States
Cardiology Associates Medical Group
Ventura, California, United States
Yale University School of Medicine
New Haven, Connecticut, United States
Delray Medical Center
Delray Beach, Florida, United States
...and 44 more locations